A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (D926NC00001; AVANZAR) - AVANZAR

AstraZeneca AB0 个研究点目标入组 1,280 人开始时间: 2022年9月29日最近更新: 2024年6月10日

研究概览

暂无简介。

•Participants = 18 years at screening
•Participants with stage IIIB or IIIC, histologically or cytologically
•documented NSCLC, not amenable for surgical resection or definitive
•chemoradiation, who have not received prior
•chemotherapy or other systemic therapy for first-line Stage IIIB, IIIC or
•IV NSCLC. Progression > 6 months after the last treatment is required
•for participants who have received prior anticancer treatment for earlystage
•Lacks sensitising EGFR tumour tissue mutation and ALK and ROS1
•rearrangements and has no documented tumour genomic alterations in
•NTRK, BRAF, RET, MET or other actionable driver oncogenes with
•approved and available therapies (actionable genomic alterations).
•Testing is not required for tumors with squamous histology, with
•exceptions.
•ECOG PS of 0 or 1
•Archival tumour tissue
•Has adequate bone marrow reserve and organ function within 7 days before randomization
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 576
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 704

•Mixed small-cell lung cancer and NSCLC histology; sarcomatoid variant of NSCLC
•History of another primary malignancy with exceptions
•Persistent toxicities caused by previous anti-cancer therapy not yet improved to Grade = 1 or baseline, with exceptions.
•Spinal cord compression or clinically or radiologically active brain metastases
•History of leptomeningeal carcinomatosis.
•Known active or uncontrolled hepatitis B or C virus infection.
•Uncontrolled or suspected infection requiring IV antibiotics, antivirals, or antifungals.
•Clinically significant corneal disease
•History of non-infectious ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or has suspected LD/pneumonitis that cannot be ruled out by imaging at screening.

发起方